High	high	O	O
incidence	incidence	O	O
of	of	O	O
primary	primary	O	B_disease
pulmonary	pulmonary	O	B_disease
hypertension	hypertension	O	S_disease
associated	associated	O	O
with	with	O	O
appetite	appetite	B_chemical	O
suppressants	suppressants	I_chemical	O
in	in	O	O
Belgium	belgium	O	O
.	.	O	O

Primary	primary	O	B_disease
pulmonary	pulmonary	O	B_disease
hypertension	hypertension	O	S_disease
is	is	O	O
a	a	O	O
rare	rare	O	O
,	,	O	O
progressive	progressive	O	O
and	and	O	O
incurable	incurable	O	O
disease	disease	O	O
,	,	O	O
which	which	O	O
has	has	O	O
been	been	O	O
associated	associated	O	O
with	with	O	O
the	the	O	O
intake	intake	O	O
of	of	O	O
appetite	appetite	O	O
suppressant	suppressant	O	O
drugs	drugs	O	O
.	.	O	O

The	the	O	O
importance	importance	O	O
of	of	O	O
this	this	O	O
association	association	O	O
was	was	O	O
evaluated	evaluated	O	O
in	in	O	O
Belgium	belgium	O	O
while	while	O	O
this	this	O	O
country	country	O	O
still	still	O	O
had	had	O	O
no	no	O	O
restriction	restriction	O	O
on	on	O	O
the	the	O	O
prescription	prescription	O	O
of	of	O	O
appetite	appetite	B_chemical	O
suppressants	suppressants	I_chemical	O
.	.	O	O

Thirty-five	thirty-five	O	O
patients	patients	O	O
with	with	O	O
primary	primary	O	B_disease
pulmonary	pulmonary	O	B_disease
hypertension	hypertension	O	S_disease
and	and	O	O
85	85	O	O
matched	matched	O	O
controls	controls	O	O
were	were	O	O
recruited	recruited	O	O
over	over	O	O
32	32	O	O
months	months	O	O
(	(	O	O
1992	1992	O	O
-	-	O	O
1994	1994	O	O
)	)	O	O
in	in	O	O
Belgium	belgium	O	O
.	.	O	O

Exposure	exposure	O	O
to	to	O	O
appetite-suppressants	appetite-suppressants	O	O
was	was	O	O
assessed	assessed	O	O
on	on	O	O
the	the	O	O
basis	basis	O	O
of	of	O	O
hospital	hospital	O	O
records	records	O	O
and	and	O	O
standardized	standardized	O	O
interview	interview	O	O
.	.	O	O

Twenty-three	twenty-three	O	O
of	of	O	O
the	the	O	O
patients	patients	O	O
had	had	O	O
previously	previously	O	O
taken	taken	O	O
appetite	appetite	B_chemical	O
suppressants	suppressants	I_chemical	O
,	,	O	O
mainly	mainly	O	O
fenfluramines	fenfluramines	O	O
,	,	O	O
as	as	O	O
compared	compared	O	O
with	with	O	O
only	only	O	O
5	5	O	O
of	of	O	O
the	the	O	O
controls	controls	O	O
(	(	O	O
66	66	O	O
versus	versus	O	O
6	6	O	O
%	%	O	O
,	,	O	O
p<0.0001	p<0.0001	O	O
)	)	O	O
.	.	O	O

Five	five	O	O
patients	patients	O	O
died	died	O	O
before	before	O	O
the	the	O	O
interview	interview	O	O
,	,	O	O
all	all	O	O
of	of	O	O
them	them	O	O
had	had	O	O
taken	taken	O	O
appetite	appetite	B_chemical	O
suppressants	suppressants	I_chemical	O
.	.	O	O

In	in	O	O
8	8	O	O
patients	patients	O	O
the	the	O	O
diagnosis	diagnosis	O	O
of	of	O	O
primary	primary	O	B_disease
pulmonary	pulmonary	O	B_disease
hypertension	hypertension	O	S_disease
was	was	O	O
uncertain	uncertain	O	O
,	,	O	O
5	5	O	O
of	of	O	O
them	them	O	O
had	had	O	O
taken	taken	O	O
appetite	appetite	B_chemical	O
suppressants	suppressants	I_chemical	O
.	.	O	O

The	the	O	O
patients	patients	O	O
who	who	O	O
had	had	O	O
been	been	O	O
exposed	exposed	O	O
to	to	O	O
appetite	appetite	B_chemical	O
suppressants	suppressants	I_chemical	O
tended	tended	O	O
to	to	O	O
be	be	O	O
on	on	O	O
average	average	O	O
more	more	O	O
severely	severely	O	O
ill	ill	O	O
,	,	O	O
and	and	O	O
to	to	O	O
have	have	O	O
a	a	O	O
shorter	shorter	O	O
median	median	O	O
delay	delay	O	O
between	between	O	O
onset	onset	O	O
of	of	O	O
symptoms	symptoms	O	O
and	and	O	O
diagnosis	diagnosis	O	O
.	.	O	O

A	a	O	O
policy	policy	O	O
of	of	O	O
unrestricted	unrestricted	O	O
prescription	prescription	O	O
of	of	O	O
appetite	appetite	B_chemical	O
suppressants	suppressants	I_chemical	O
may	may	O	O
lead	lead	O	O
to	to	O	O
a	a	O	O
high	high	O	O
incidence	incidence	O	O
of	of	O	O
associated	associated	O	O
primary	primary	O	B_disease
pulmonary	pulmonary	O	B_disease
hypertension	hypertension	O	S_disease
.	.	O	O

Intake	intake	O	O
of	of	O	O
appetite	appetite	B_chemical	O
suppressants	suppressants	I_chemical	O
may	may	O	O
accelerate	accelerate	O	O
the	the	O	O
progression	progression	O	O
of	of	O	O
the	the	O	O
disease	disease	O	O
.	.	O	O

